← Russell 3000 cross-section

TNXP Tonix Pharmaceuticals Holding Corp.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$234m
Revenue TTM
$29m
Net income TTM
$-160m
Free cash flow
$-158m
Composite score
41.9
Sector rank
#2793

Valuation

P / E
EV / EBITDA
EV / sales
2.0
FCF yield
-67.49%
Earnings yield vs 10-yr
-72.90pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-548.6%
EBITDA margin
-561.1%
ROE
-71.8%
ROIC
-359.2%
Revenue growth
196.0%

Insider activity, last 90 days

Net open-market
$0.14m
Buyers
4
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue recognized for the three months ended June 30, 2026 and 2025, was $13.5 million and $2.0 million, respectively. Gross-to-net allowances decreased by approximately $1.3 million due to changes in prior estimates related to a prior year resulting in an additional $1.3 million of revenue being recognized during the three months ended June 30, 2026. Cost of sales recognized for the three months ended June 30, 2026 and 2025, was $0.7 million and $3.3 million, respectively. The decrease in cost of sales is driven by a change in product mix and sale of product which had previously been written off. …Tonix Pharmaceuticals Holding Corp., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →